Cancer Immunotherapy

Cancer is the world's second largest cause of death, according to the Nobel Assembly. Until recently, cancer treatment has relied on four options: surgery, radiation, chemotherapy and targeted therapy. The success of immunotherapy has emerged as a new fifth pillar by some defined as a new era in the treatment of cancer.

In December 2018, two immunologists-American James Allison and Japan’s Tasuku Honjo-were awarded the Nobel Prize in medicine for pioneering a way to re-program a person’s immune system to attack cancer cells.

In this seminar Klas Kärre (professor at KI and member of the Nobel Committee) will explain Allison’s and Hoino’s research as well as previous research by others in this field that may offer new opportunities today.

In this seminar we will also present Swedish research in the field today. Hans Gustav-Ljunggren (professor at KI and member of the Nobel Committee) will share his insights in the development of new cell based therapies (with a focus on NK cells), and associate professor Alex Karlsson-Parra (Chief Scientific Officer at Immunicum AB) will present Immunicum’s lead development candidate (ilixandencel) using specifically activated dendritic cells for treating cancer.

We hope you are able to join us for a discussion of a very interesting field of research and development that may offer promising opportunities for Swedish life sciences!